Zymeworks Inc. (ZYME) stock is soaring nearly 9% in pre-market trading on Wednesday after Leerink Partners analyst upgraded the biopharmaceutical company's rating from Market Perform to Outperform.
The analyst action seems to be driving the significant upward movement in Zymeworks' stock price ahead of the regular trading session. Financial details and rationale behind the rating upgrade were not provided in the brief news summary.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.